Cowa LLC Acquires Shares of 7,097 AtriCure, Inc. (NASDAQ:ATRC)

Cowa LLC acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 7,097 shares of the medical device company’s stock, valued at approximately $217,000.

A number of other institutional investors have also added to or reduced their stakes in ATRC. Creative Planning purchased a new stake in AtriCure during the 3rd quarter valued at approximately $321,000. Assenagon Asset Management S.A. boosted its position in shares of AtriCure by 151.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock valued at $6,425,000 after acquiring an additional 138,046 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in shares of AtriCure during the 3rd quarter valued at approximately $28,000. Emerald Advisers LLC boosted its position in shares of AtriCure by 10.9% during the 3rd quarter. Emerald Advisers LLC now owns 389,836 shares of the medical device company’s stock valued at $10,931,000 after acquiring an additional 38,421 shares during the last quarter. Finally, QRG Capital Management Inc. bought a new position in shares of AtriCure during the 3rd quarter valued at approximately $276,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Trading Down 2.0 %

AtriCure stock opened at $38.39 on Friday. The company has a quick ratio of 2.59, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -40.41 and a beta of 1.46. The stock has a 50-day moving average price of $36.23 and a 200 day moving average price of $31.85.

Analyst Upgrades and Downgrades

ATRC has been the subject of a number of research reports. UBS Group increased their target price on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and set a $51.00 target price on shares of AtriCure in a research report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $60.00 target price on shares of AtriCure in a research report on Monday, February 10th. Canaccord Genuity Group increased their target price on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Stifel Nicolaus increased their target price on AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.